Humana (HUM) Stock Forecast & Price Target

Humana
Bull Case

Here are some ways that investors could benefit from investing in Humana Inc.:

• Humana Inc. recently reported strong second-quarter results, beating consensus estimates with earnings per share of $7.61 against an expected $7.27, while revenue grew 26.2% year-over-year to $40.89 billion, demonstrating robust operational performance and top-line growth that supports the current stock price of $406.23.
• The company has received significant positive momentum from Wall Street, with Barclays raising its rating to "overweight" and lifting its price target to $515.00, while Royal Bank of Canada and Truist Financial both raised their targets to $415.00, indicating strong institutional confidence in the stock's potential to outperform the sector.
• Humana Inc. is expanding its specialized-care options and maintaining affordable Medicare Advantage plans for 2027, a strategic move that could support member retention and strengthen its competitive position during the critical annual enrollment period, potentially driving future membership growth.
• Short interest in the stock has declined significantly over the past few months, dropping from over 6 million shares in June to approximately 2.8 million shares in September, suggesting that bearish sentiment is fading and that short sellers are covering their positions, which can create upward pressure on the stock price.
• With a beta of 0.74, Humana Inc. exhibits lower volatility than the broader market, making it a potentially stable investment for risk-averse investors, while its dividend yield of 0.93% provides a modest income stream alongside capital appreciation potential.